Filing Analysis
Sanuwave Health, Inc. issued an 8-K to announce the release of its financial results for the second quarter ended June 30, 2026. The company scheduled a business update conference call for August 7, 2026.
📋 Key Facts
- Financial results for Q2 ended June 30, 2026, were released on August 6, 2026.
- A business update conference call is scheduled for August 7, 2026, at 8:30 am EST.
- The filing includes a press release as Exhibit 99.1.
Sanuwave Health, Inc. issued an 8-K to announce the release of preliminary financial results for the fiscal quarter ended June 30, 2026.
📋 Key Facts
- The company announced preliminary financial results for the quarter ending June 30, 2026.
- The announcement was made via a press release dated July 13, 2026.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Sanuwave Health, Inc. issued a press release on June 16, 2026, providing updated financial guidance for the quarter ending June 30, 2026.
📋 Key Facts
- The company issued updated guidance for the quarter ended June 30, 2026.
- The announcement was made via a press release (Exhibit 99.1) on June 16, 2026.
- The filing is submitted under Item 7.01 (Regulation FD Disclosure), meaning the information is 'furnished' rather than 'filed'.
Sanuwave Health, Inc. reported the results of its 2026 annual meeting of stockholders held on June 11, 2026. Stockholders voted to elect five directors, ratify the appointment of Baker Tilly US, LLP as the independent auditor, and approve executive compensation in a non-binding vote.
📋 Key Facts
- Annual meeting of stockholders held on June 11, 2026.
- Five directors elected: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler.
- Baker Tilly US, LLP ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation was approved via an advisory, non-binding vote (4,666,444 votes for vs 385,238 against).
SANUWAVE Health, Inc. announced its financial results for the first quarter ended March 31, 2026. The company has scheduled a conference call for May 13, 2026, to discuss the results and provide a business update.
📋 Key Facts
- Financial results for the first quarter ended March 31, 2026, were released on May 12, 2026.
- A business update conference call is scheduled for May 13, 2026, at 8:30 am EST.
- The filing includes Exhibit 99.1, which is the press release detailing the financial performance.
- The information is furnished under Item 2.02 and is not deemed 'filed' for regulatory purposes.
SANUWAVE Health, Inc. announced preliminary financial results for the first quarter ended March 31, 2026, via a press release on April 16, 2026. The disclosure was made under Item 2.02, providing a routine update on the company's financial condition.
📋 Key Facts
- Preliminary financial results for the quarter ended March 31, 2026, were announced on April 16, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The registrant is listed on The Nasdaq Stock Market LLC under the ticker SNWV.
SANUWAVE Health, Inc. issued a press release on March 26, 2026, announcing its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a follow-up conference call and business update for March 27, 2026.
📋 Key Facts
- Financial results announced for Q4 and fiscal year ended December 31, 2025.
- Conference call scheduled for March 27, 2026, at 8:30 am EST.
- The filing includes Exhibit 99.1, the press release detailing the financial performance.
- The report was signed by Peter Sorensen, Chief Financial Officer.
SANUWAVE Health, Inc. has determined that its audited financial statements for fiscal year 2024 and unaudited statements for all quarters in 2024 and 2025 can no longer be relied upon due to unrecorded sales and use tax liabilities. The company expects to record a significant increase in liabilities and expenses following a nexus study that identified historical tax obligations.
🚩 Red Flags
- Non-reliance on multiple years of previously issued audited and unaudited financial statements.
- Significant unrecorded tax liabilities ($4.9M-$5.2M) relative to typical micro-cap balance sheets.
- Potential identification of new material weaknesses in internal controls.
- The issue spans the tenure of both current (Baker Tilly) and former (Marcum) auditors.
📋 Key Facts
- Item 4.02 filing triggered by a third-party sales and use tax nexus study.
- Affected periods include the full year 2024 and the first three quarters of both 2024 and 2025.
- Estimated aggregate increase in reported liabilities is between $4.9 million and $5.2 million as of December 31, 2025.
- Estimated increase in expenses for 2024 is $1.6 million to $1.8 million, and for 2025 is $1.7 million to $1.9 million.
- Management is evaluating whether this matter results in additional material weaknesses in internal control over financial reporting.
- The restated figures will be included in the 2025 Form 10-K.
This is an amendment to a previously filed 8-K (Form 8-K/A) regarding the results of the 2025 annual meeting. The company is disclosing its decision to hold advisory votes on executive compensation frequency every one year.
📋 Key Facts
- The filing is an amendment to an August 19, 2025, Form 8-K regarding voting results from the Annual Meeting held on August 19, 2025.
- Stockholders voted on the frequency of advisory votes for named executive officer compensation.
- The 'every one year' option received the highest number of votes cast, aligning with Board recommendations.
- The Board determined on January 7, 2026, that such advisory votes will occur every year until at least the 2031 annual meeting.
Sanuwave Health, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2025.
📋 Key Facts
- The company issued a press release on November 7, 2025, regarding Q3 2025 financial results.
- A business update conference call was scheduled for November 7, 2025, at 8:30 am EST.
- Financial materials are made available via the company's investor relations website.
Sanuwave Health, Inc. announced the termination of its President, Andrew Walko, effective October 24, 2025. The departure was noted as being 'without cause,' and a separation agreement has been executed.
🚩 Red Flags
- Departure of a key executive (President) can sometimes signal internal friction or strategic shifts, though 'without cause' typically mitigates immediate alarm.
📋 Key Facts
- Andrew Walko terminated as President on October 24, 2025 (Separation Date).
- Termination was 'without cause'.
- Severance package includes $76,666.67 in cash, equivalent to approximately four months and one week of base salary.
- Cash payments will be made in equal installments over a four-month Severance Period starting October 31, 2025.
- Employee stock options will continue to vest during the Severance Period.
Sanuwave Health, Inc. announced significant leadership restructuring on September 25, 2025, including the termination of President Andrew Walko and the removal of Peter Stegagno from the COO role.
🚩 Red Flags
- Termination of the President (Andrew Walko) creates a leadership vacuum as the company does not intend to appoint a successor immediately.
- Significant management churn: The COO is being replaced and the President is being terminated within the same filing.
- The reclassification of Peter Stegagno from 'executive officer' suggests a significant reduction in his authority or scope of responsibility.
📋 Key Facts
- Andrew Walko (President) was terminated without cause, effective October 24, 2025; no replacement is being sought at this time.
- Daniel Coyle appointed as Chief Operating Officer (COO), moving up from VP of Engineering and Operations.
- Peter Stegagno removed as COO and transitioned to Chief Regulatory Officer; the Board determined he no longer meets the definition of an 'executive officer'.
- Daniel Coyle's annualized base salary increased to $225,000 with a 40% annual cash bonus opportunity.
- 60,000 stock options granted to Daniel Coyle, vesting in 12 equal quarterly installments starting October 9, 2025.
Sanuwave Health, Inc. has entered into a new $28 million credit facility consisting of a $23 million secured term loan and a $5 million revolving credit line. The proceeds were used to retire existing debt under a previous Note and Warrant Purchase Agreement (NWPSA).
🚩 Red Flags
- Debt is secured by substantially all tangible and intangible assets (all-asset lien).
- Strict financial covenants (leverage and fixed charge coverage) could trigger default if cash flow fluctuates.
- Refinancing of existing debt suggests a need to restructure obligations or manage liquidity.
📋 Key Facts
- Entered into Credit Agreement on September 25, 2025.
- Facility includes a $23.0 million secured term loan maturing September 25, 2029.
- Facility includes a $5.0 million secured revolving credit facility maturing September 25, 2027.
- Interest rates: SOFR + 3.50% (term) or Base Rate + 2.50% (revolver).
- The debt is secured by a lien on substantially all tangible and intangible assets of the Company and guarantors.
- Financial covenants include a maximum total leverage ratio of 2.50:1.00 and a minimum fixed charge coverage ratio of 1.25:1.00.
- Proceeds used to fully repay and terminate the NWPSA dated August 6, 2020.
Sanuwave Health, Inc. announced that a third-party licensee has exercised its option to acquire the company's portfolio of intravascular shockwave application patents. This exercise results in a $5.0 million cash payment to the company.
🚩 Red Flags
- Asset disposition: The company is selling off its core intellectual property (patents) in a specific field, which may impact long-term revenue potential if they no longer hold exclusive rights to these technologies.
📋 Key Facts
- Licensee exercised an option on August 21, 2025, to acquire a patent portfolio related to intravascular shockwave applications.
- The transaction includes a $5.0 million cash payment to Sanuwave Health, Inc.
- This follows a previous exclusive license and option agreement entered into on March 6, 2024.
- An initial one-time payment of $2.5 million was previously made under the original agreement.
Sanuwave Health, Inc. held its 2025 annual meeting of stockholders on August 19, 2025, where shareholders approved the election of five directors and an amendment to the 2024 Equity Incentive Plan.
📋 Key Facts
- Stockholders approved increasing the total number of shares authorized under the 2024 Equity Incentive Plan by 500,000 shares (Proposal 3).
- Five directors were elected: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler.
- The appointment of Baker Tilly US, LLP as independent registered public accounting firm for FY2025 was ratified.
- Shareholders approved an advisory 'Say-on-Pay' vote regarding executive compensation.
- Shareholders voted in favor of a 1-year frequency for future non-binding compensation votes.
Sanuwave Health, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2025. The company scheduled a business update conference call for August 8, 2025.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 8, 2025.
- The company issued a press release regarding financial results and scheduled a business update call for 8:30 am EST on the filing date.
Sanuwave Health, Inc. announced the details of a Separation and Release Agreement with former Chief Commercial Officer Nanci Gilmore following her termination without cause on May 30, 2025.
🚩 Red Flags
- Departure of a C-suite officer (Chief Commercial Officer) can sometimes signal shifts in commercial strategy or internal friction, though this was noted as 'without cause'.
📋 Key Facts
- Nanci Gilmore was terminated without cause effective May 30, 2025.
- Separation Agreement entered into on July 28, 2025.
- Lump sum cash payment includes five months' annual base salary ($97,916.70) and a pro-rated bonus ($14,790.81).
- Employee stock options will continue to vest through January 31, 2026.
Sanuwave Health, Inc. issued an 8-K to announce the release of preliminary financial results for the quarter ended June 30, 2025.
📋 Key Facts
- The filing was made on July 14, 2025.
- The company announced preliminary financial results for the fiscal quarter ending June 30, 2025.
- Information is provided via a press release attached as Exhibit 99.1.
Sanuwave Health, Inc. has announced the scheduling of its 2025 Annual Meeting of Stockholders for August 19, 2025. The filing outlines key dates for record holders and deadlines for stockholder proposals or director nominations.
🚩 Red Flags
- The company did not hold an annual meeting of stockholders in 2024.
📋 Key Facts
- Annual Meeting Date: August 19, 2025
- Record Date for voting eligibility: July 8, 2025
- Deadline for shareholder proposals (Rule 14a-8): July 7, 2025
- Deadline for director nominations/proposals under Bylaws: July 7, 2025
- Deadline for universal proxy rule compliance (Rule 14a-19): July 7, 2025
Sanuwave Health, Inc. announced the termination of its Chief Commercial Officer, Nanci Gilmore, without cause on May 30, 2025. The company simultaneously appointed Dustin Libby as Executive Vice President of Commercial Operations to fill the leadership gap.
🚩 Red Flags
- Sudden departure of a C-level officer (CCO) can sometimes signal internal friction, though 'without cause' typically implies a standard separation or restructuring rather than misconduct.
📋 Key Facts
- Nanci Gilmore (Chief Commercial Officer) terminated without cause effective May 30, 2025.
- Ms. Gilmore is entitled to $97,916.67 in cash severance (equivalent to five months of base salary), subject to release of claims and restrictive covenants.
- Dustin Libby appointed as Executive Vice President of Commercial Operations effective June 3, 2025.
Sanuwave Health, Inc. announced the resignation of Board member A. Michael Stolarski and the simultaneous appointment of Gregory Bazar to the Board and Compensation Committee.
🚩 Red Flags
- None identified; resignation was explicitly stated as not being due to a disagreement.
📋 Key Facts
- A. Michael Stolarski resigned from the Board effective May 27, 2025.
- The company stated Mr. Stolarski's resignation was not due to any disagreement with the Company or management.
- Gregory Bazar appointed to the Board and Compensation Committee effective May 27, 2025.
- Mr. Bazar received a grant of 41,333 stock options at an exercise price of $27.97 per share.
- Options vest in 12 equal quarterly installments over three years.
- Mr. Bazar will receive quarterly grants of fully vested stock options valued at $20,000 each.
Sanuwave Health, Inc. has finalized the engagement of Baker Tilly US, LLP as its new independent registered public accounting firm, replacing CBIZ CPAs P.C.
🚩 Red Flags
- Change in certifying accountant (Item 4.01) can sometimes signal underlying disagreements or internal control issues, though no such disagreements were reported here.
📋 Key Facts
- The Company dismissed CBIZ CPAs P.C. on May 12, 2025.
- Baker Tilly US, LLP has completed client acceptance procedures and signed an engagement letter on May 20, 2025.
- The new auditor will serve for the fiscal year ending December 31, 2025.
- Engagement is effective starting with the review of condensed consolidated financial statements for the quarter ending June 30, 2025.
Sanuwave Health, Inc. has dismissed its independent auditor, CBIZ CPAs P.C., and appointed Baker Tilly US, LLP to serve as the new independent registered public accounting firm effective for the Q2 2025 review.
🚩 Red Flags
- Auditor change occurring shortly after the disclosure of material weaknesses in internal controls (reported in March 31, 2025 10-Q).
- Material weaknesses identified include lack of internal controls over key accounting/IT processes and insufficient expertise to apply U.S. GAAP to complex transactions and financial instruments.
📋 Key Facts
- Dismissed CBIZ CPAs P.C. on May 12, 2025.
- Engaged Baker Tilly US, LLP to serve as the new independent auditor starting with the June 30, 2025 quarterly review.
- The company reported no disagreements with CBIZ CPAs regarding accounting principles or auditing procedures during their tenure (April 11, 2025 – May 12, 2025).
- The dismissal follows the disclosure of material weaknesses in internal control over financial reporting as noted in the Q1 2025 10-Q.
Sanuwave Health, Inc. filed an 8-K to announce the release of its financial results for the first quarter ended March 31, 2025. The company also scheduled a business update conference call for May 9, 2025.
📋 Key Facts
- Financial results for Q1 ended March 31, 2025, were released on May 9, 2025.
- A business update via conference call was scheduled for May 9, 2025, at 8:30 am EST.
- The filing includes a press release as Exhibit 99.1.
Sanuwave Health, Inc. has replaced its independent auditor, Marcum LLP, with CBIZ CPAs P.C., effective April 11, 2025. While no disagreements were reported regarding accounting principles, the company's previous audits included going concern warnings and disclosed material weaknesses in internal controls.
🚩 Red Flags
- Going concern language in previous audit reports for years ended Dec 31, 2023, and Dec 31, 2024.
- Previously disclosed material weaknesses in the Company's internal control over financial reporting (ICFR) for FY 2023 and FY 2024.
- Auditor change occurring alongside ongoing liquidity/going concern concerns.
📋 Key Facts
- Marcum LLP resigned as independent auditor on April 10, 2025.
- CBIZ CPAs P.C. was engaged to serve as the new independent auditor effective for the review of Q1 2025 financial statements.
- The change follows CBIZ CPAs' acquisition of Marcum's attest business on November 1, 2024.
- Previous audits (FY 2023 and FY 2024) included a paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
Sanuwave Health, Inc. issued an 8-K to announce the release of preliminary financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- The filing was made on April 8, 2025.
- The company is reporting preliminary financial results for the quarter ending March 31, 2025.
- Information provided under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Sanuwave Health, Inc. announced that its subsidiary entered into a new 60-month lease for the company's headquarters in Eden Prairie, Minnesota.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Effective date of lease: March 27, 2025.
- Monthly base rent: $21,687.25.
- Rent escalation: Annual increase of 3.5%.
- Lease term: 60 months with a five-year extension option.
- Additional costs: Tenant is responsible for pro rata share of property taxes and operating expenses.
Sanuwave Health, Inc. filed an 8-K to announce the release of its financial results for the fourth quarter and fiscal year ended December 31, 2024. The company also scheduled a business update conference call for March 21, 2025.
📋 Key Facts
- Reported date: March 21, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The company issued a press release regarding financial results on the filing date.
- A business update conference call was scheduled for March 21, 2025, at 8:30 am EST.
Sanuwave Health, Inc. announced its successful uplisting to the Nasdaq Global Market effective March 7, 2025. In preparation for this transition, the company amended and restated its bylaws and adopted a new Code of Business Conduct and Ethics.
🚩 Red Flags
- Bylaw amendments include restrictive measures such as prohibiting stockholders from calling special meetings and implementing strict requirements for proxy solicitation (Rule 14a-19).
📋 Key Facts
- Uplisting to Nasdaq Global Market effective at market open on March 7, 2025, under ticker 'SNWV'.
- Board approved Amended and Restated Bylaws on March 4, 2025.
- Bylaw changes include: prohibiting special meetings, increasing max directors from 9 to 10, and establishing Clark County, Nevada as the exclusive legal forum.
- New Code of Business Conduct and Ethics adopted on March 4, 2025.
- Received Nasdaq Listing Qualifications Staff approval for uplisting.
Sanuwave Health, Inc. announced the separation of Timothy Hendricks from his role as Executive Vice President of Sales, effective January 3, 2025. The company entered into a severance agreement providing five months of base salary and continued option vesting.
🚩 Red Flags
- Departure of a key sales executive (EVP of Sales) can impact revenue momentum.
📋 Key Facts
- Timothy Hendricks separated as EVP of Sales on January 3, 2025.
- Separation and Release Agreement was executed on January 13, 2025.
- Severance includes five months' annual base salary totaling $104,116.67.
- Employee stock options will continue to vest through May 31, 2024 (Note: potential typo in filing text regarding year).
Sanuwave Health, Inc. issued a press release announcing preliminary financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- The filing relates to preliminary financial results for the period ending December 31, 2024.
- Results were announced via a press release dated January 13, 2025.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Sanuwave Health, Inc. announced the departure of Timothy Hendricks from his role as EVP of Sales on January 3, 2025. The company has appointed Timothy Wern as his successor to lead sales operations.
🚩 Red Flags
- Departure of a key executive (EVP of Sales) while separation terms are still being negotiated.
📋 Key Facts
- Timothy Hendricks separated from service as Executive Vice President of Sales effective January 3, 2025.
- The terms of a separation agreement for Mr. Hendricks are currently being negotiated.
- Timothy Wern appointed as the new Executive Vice President of Sales effective January 6, 2025.
- Mr. Wern has previous leadership experience at HeartWare International (Medtronic) and Abiomed (Johnson & Johnson).
Sanuwave Health, Inc. announced the resignation of director Kevin A. Richardson, II, effective November 12, 2024. The departure was part of a mutual agreement that includes non-disparagement covenants and an amendment to his stock option vesting.
🚩 Red Flags
- Accelerated vesting of stock options upon director resignation can sometimes indicate a negotiated exit settlement.
📋 Key Facts
- Kevin A. Richardson, II resigned as a director on November 12, 2024.
- The resignation is governed by an 'Acknowledgment and Mutual Agreement' including mutual non-disparagement covenants.
- An Amendment to Stock Option Agreement was executed, causing 66,667 options granted on October 22, 2024, to fully vest immediately.
- These vested options remain exercisable until their expiration date of October 22, 2034.
Sanuwave Health, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a notification of Q3 2024 financial results announcement.
- A business update conference call was scheduled for November 8, 2024, at 8:30 am EST.
- Financial materials are made available on the company's investor relations website.
Sanuwave Health, Inc. announced the granting of stock options to several current and former executive officers under its 2024 Equity Incentive Plan on October 22, 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Grant date for all options: October 22, 2024.
- Exercise price per share: $14.20 (equal to the closing price on the grant date).
- Vesting schedule: 12 equal quarterly installments over three years.
- Option term: 10 years.
- Recipients include Morgan Frank (160,000 options), Peter Sorensen (88,000 options), Tim Hendricks (50,667 options), and Kevin A. Richardson, II (66,667 options).
Sanuwave Health, Inc. implemented a 1-for-375 reverse stock split and executed a $10.3 million private placement to address liquidity issues and existing defaults. The company also entered into a consent and waiver with noteholders to forestall remedies related to events of default.
🚩 Red Flags
- Extreme reverse stock split (1-for-375) often indicates severe share price erosion.
- Multiple existing events of default on the NWPSA agreement.
- Requirement to maintain $5.0 million liquidity as a condition for debt forbearance.
- Significant dilution resulting from the conversion of notes and warrants into common stock.
📋 Key Facts
- Implemented a 1-for-375 reverse stock split effective October 18, 2024.
- Closed a private placement of approximately 1.3 million shares at $8.25 per share (post-split), raising ~$10.3 million in gross proceeds.
- Entered into a Consent and Limited Waiver with noteholders to forbear on remedies regarding existing events of default until Dec 31, 2024.
- The waiver is contingent upon the company maintaining at least $5.0 million in liquidity following transactions.
- Exchanged outstanding Future Advance Convertible Promissory Notes and Warrants for 3,989,456 shares of common stock via a cashless exchange/conversion.
Sanuwave Health, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- The filing is a notification of Q2 2024 financial results announcement.
- A business update conference call was scheduled for August 13, 2024, at 8:30 am EST.
- Financial materials are made available on the company's investor relations website.
SANUWAVE Health, Inc. announced that stockholders approved a significant reverse stock split via consent solicitation on August 7, 2024. The split ratio will range between 1-for-300 and 1-for-500, as determined by the Board.
🚩 Red Flags
- Extreme reverse stock split ratio (up to 1-for-500) typically indicates severe share price erosion and potential delisting risk.
- The massive number of shares authorized under the new Equity Incentive Plan (over 516 million shares) suggests significant future dilution.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio between 1-for-300 and 1-for-500 on August 7, 2024.
- The company also approved the SANUWAVE Health, Inc. 2024 Equity Incentive Plan.
- The 2024 Equity Incentive Plan allows for the issuance of up to 516,208,834 shares of common stock.
- Approval was obtained via a Consent Solicitation commenced on July 18, 2024.
Sanuwave Health, Inc. entered into a Sixth Amendment to its Note and Warrant Purchase Agreement (NWPSA) to address existing events of default. The amendment provides for forbearance on remedies until December 31, 2024, but includes significant additional fees and interest penalties.
🚩 Red Flags
- Existing events of default are currently being forborne, indicating liquidity or covenant issues.
- Significant accumulation of 'default interest' and 'deferred interest' which increases the total debt burden.
- The forbearance period is short (ending Dec 31, 2024), creating a looming deadline for restructuring or refinancing.
📋 Key Facts
- Entered into the 'Sixth Amendment' to the NWPSA on July 15, 2024.
- Holders agreed to forbear exercising remedies for existing events of default until December 31, 2024 (or until a new event of default occurs).
- A consent fee of $670,841 was added to the principal amount as of June 30, 2024.
- Deferred interest for the March 31, 2024 period is $163,519; default interest is $272,532.
- Future quarterly interest will include deferred and default interest calculated on the beginning-of-quarter principal.
Sanuwave Health, Inc. filed an 8-K to announce the issuance of a press release containing preliminary financial results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: July 10, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing contains preliminary financial results via Exhibit 99.1
- Signed by Peter Sorensen, Chief Financial Officer
Sanuwave Health, Inc. has officially terminated its Merger Agreement with SEP Acquisition Corp., which was originally entered into on August 23, 2023. This termination ends the planned merger where Sanuwave would have become a wholly-owned subsidiary of SEPA.
🚩 Red Flags
- Failure of a previously announced merger/acquisition deal often indicates significant hurdles in due diligence, financing, or strategic alignment.
- Termination of material agreements can lead to increased volatility and uncertainty regarding the company's future growth trajectory and capital structure.
📋 Key Facts
- The Company delivered notice to terminate the Merger Agreement on June 25, 2024.
- The original agreement was dated August 23, 2023, involving SEP Acquisition Corp. and its subsidiary SEP Acquisition Holdings Inc.
- The termination effectively cancels the transaction where Sanuwave would have become a subsidiary of SEPA.
Sanuwave Health, Inc. entered into a $1.8 million private placement involving convertible promissory notes and significant warrants to provide immediate liquidity. The filing also reveals complex related-party transactions and terms tied to an upcoming business combination with SEP Acquisition Corp.
🚩 Red Flags
- Highly dilutive warrant structure (65 million total warrants) at very low exercise prices ($0.04 - $0.067).
- Related-party transaction: Manchester Explorer, L.P. is a >5% owner and its portfolio manager serves as the Company's CEO/Chairman.
- Potential for massive dilution via conversion of notes at $0.04 per share.
- Complex 'Letter Agreement' allowing purchasers to exchange warrants for common stock at specific ratios upon a business combination or reverse split.
📋 Key Facts
- Total proceeds of $1.8 million received on June 18, 2024 ($1.3M from private placement, $0.5M from a promissory note).
- Issuance of future advance convertible promissory notes totaling $1.3 million with a 15% annual interest rate.
- Issuance of two tranches of warrants: 32.5 million shares at $0.067 and 32.5 million shares at $0.04 per share.
- Conversion price for notes is set at $0.04, subject to downward adjustments if the stock price or listing conditions are not met.
- A $0.5 million promissory note was issued to Manchester Explorer, L.P., maturing December 18, 2024, at 15% interest.
- Purchasers received a waiver regarding the company's obligation to perform a reverse stock split by Dec 31, 2023.
Sanuwave Health, Inc. reported a significant withdrawal of its Nasdaq listing application for the proposed merger with SEPA and disclosed a $2.075 million settlement to extinguish a $6.3 million debt to Celularity, Inc.
🚩 Red Flags
- Nasdaq listing failure: The combined entity failed to meet Nasdaq requirements, necessitating a move to a different exchange (Cboe BZX).
- Significant debt settlement: Paid $2.075M to settle a much larger $6.3M obligation, indicating high interest or significant discount/haircut.
- Liquidity pressure: The debt settlement required immediate capital from recent fundraising.
📋 Key Facts
- The company withdrew its Nasdaq listing application for the combined entity (Sanuwave/SEPA) because it was unlikely to meet Nasdaq requirements.
- A new application to list on the Cboe BZX Exchange, Inc. is currently under review.
- On June 3, 2024, the company paid $2.075 million to settle and extinguish a $6.3 million note/interest owed to Celularity, Inc.
- The debt settlement was funded via a recent capital raise involving longtime shareholders.
Sanuwave Health, Inc. entered into Amendment Number Three to its Merger Agreement with SEP Acquisition Corp. (SEPA). The amendment extends the transaction's 'Outside Date' and grants Sanuwave a unilateral right to terminate the merger.
🚩 Red Flags
- Extension of 'Outside Date' suggests potential delays in meeting closing conditions or regulatory approvals.
- Risk noted regarding SEPA's requirement to have at least $12.0 million at closing from Class A common stock and private placement.
📋 Key Facts
- Amendment Number Three was executed on May 28, 2024.
- The 'Outside Date' for the merger has been extended from May 31, 2024, to June 30, 2024.
- Sanuwave Health, Inc. now holds a unilateral right to terminate the Merger Agreement at any time upon written notice to SEPA.
- The amendment does not change other terms of the original August 23, 2023, Merger Agreement.
Sanuwave Health, Inc. filed an 8-K to announce the release of its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that earnings materials and a business update conference call were scheduled for May 10, 2024.
📋 Key Facts
- Reported date: May 10, 2024
- Reporting period: First quarter ended March 31, 2024
- The company issued a press release regarding financial results via Item 2.02.
- A business update conference call was scheduled for May 10, 2024, at 8:30 am EST.
Sanuwave Health, Inc. has entered into an amendment to its merger agreement with SEP Acquisition Corp. (SEPA), extending the transaction's 'Outside Date' from April 30, 2024, to May 31, 2024.
🚩 Red Flags
- Extension of merger deadline suggests potential delays in meeting closing conditions or regulatory approvals.
- Risk noted regarding SEPA's ability to maintain Nasdaq listing following the transaction.
- Dependency on SEPA securing $12.0 million in specific capital sources to close.
📋 Key Facts
- Amendment Number Two to the Agreement and Plan of Merger was signed on April 25, 2024.
- The 'Outside Date' for the merger has been extended from April 30, 2024, to May 31, 2024.
- SEPA is required to have at least $12.0 million at closing from Class A common stock non-redemption and a private placement.
SANUWAVE Health, Inc. issued a press release announcing preliminary financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing is an announcement of preliminary financial results via Exhibit 99.1.
- Reporting period: Quarter ended March 31, 2024.
- Date of report: April 10, 2024.
Sanuwave Health, Inc. announced the termination of CFO Toni Rinow without cause and the simultaneous appointment of Peter Sorensen as the new CFO effective April 1, 2024.
🚩 Red Flags
- Sudden departure of the CFO (even if 'without cause') can sometimes signal internal friction or disagreements over financial reporting/strategy.
- Significant cash outflow for severance ($335,000) in a micro-cap context.
📋 Key Facts
- CFO Toni Rinow was terminated without cause on March 28, 2024.
- Severance for Dr. Rinow includes one year's base salary totaling $335,000, payable in equal installments.
- Peter Sorensen appointed as CFO and Principal Financial Officer effective April 1, 2024.
- Sorensen's compensation includes a $225,000 annual base salary and potential bonus of up to 40% of base salary.
- Sorensen's offer includes an option to purchase 105,000 shares of common stock, subject to a three-year vesting schedule.
SANUWAVE Health, Inc. filed an 8-K to announce the release of its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal notice that earnings materials are being made available via press release and conference call.
📋 Key Facts
- Reported date: March 22, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The company held a business update conference call on March 22, 2024, at 8:30 am EST
- Financial results were disseminated via press release (Exhibit 99.1)
Sanuwave Health, Inc. entered into a Fifth Amendment to its Note and Warrant Purchase Agreement (NPA) to facilitate the licensing of key patents. The agreement includes a waiver of defaults related to this transaction and provides forbearance on existing defaults until April 30, 2024.
🚩 Red Flags
- Existing events of default are currently being forborne by noteholders.
- Interest on outstanding debt is accruing at a 'default rate' during the forbearance period, increasing the cost of capital.
- The company is reliant on a single $2.5 million infusion and an uncertain option exercise to manage its immediate liquidity/debt obligations.
- Forbearance deadline of April 30, 2024, creates a significant near-term liquidity cliff.
📋 Key Facts
- Entered into a 'Fifth Amendment' with NH Expansion Credit Fund Holdings LP (the Agent) and noteholders on March 6, 2024.
- The amendment consents to Sanuwave, Inc. entering an exclusive license and option agreement for intravascular shockwave patents.
- The Licensee is paying a one-time fee of $2.5 million for the exclusive license.
- The Licensee has an option to acquire the Patents for an additional 'single-digit millions' payment.
- Noteholders agreed to waive defaults arising from this specific transaction and release the Patents from collateral.
- Holders will forbear exercising remedies on existing events of default until April 30, 2024, or until another event of default occurs.
- Outstanding obligations under the NPA continue to accrue interest at the default rate during the forbearance period.
Sanuwave Health, Inc. entered into an amendment to its merger agreement with SEP Acquisition Corp. (SEPA), extending the transaction's 'Outside Date' from February 28, 2024, to April 30, 2024.
🚩 Red Flags
- Extension of merger deadline suggests potential delays in meeting closing conditions or regulatory approvals.
- Risk noted regarding SEPA's ability to maintain Nasdaq listing following the transaction.
- Requirement for SEPA to secure $12.0 million in specific funding sources at closing.
📋 Key Facts
- Amendment Number One extends the termination deadline (Outside Date) for the merger with SEPA to April 30, 2024.
- The original Outside Date was February 28, 2024.
- No other changes were made to the existing Merger Agreement dated August 23, 2023.
- SEPA must have at least $12.0 million at closing from Class A common stock and private placement proceeds.
Sanuwave Health, Inc. shareholders have approved a merger agreement with SEP Acquisition Corp. (SEPA), facilitating a business combination that will result in the company becoming a subsidiary of SEPA.
🚩 Red Flags
- Transaction involves a SPAC-style business combination (SEP Acquisition Corp.), which carries inherent execution risks.
- Risk factor noted regarding the requirement that SEPA must have at least $12.0 million at closing from specific sources (Class A common stock and private placement).
📋 Key Facts
- Special Meeting held on February 21, 2024.
- Proposal 1: Approval of the Agreement and Plan of Merger with SEP Acquisition Corp. (SEPA) was approved by shareholders.
- Proposal 2: Adjournment of the Special Meeting to solicit additional proxies was also approved, though deemed unnecessary as sufficient votes were already obtained.
- The transaction will result in Sanuwave Health, Inc. becoming a subsidiary of SEPA.
Sanuwave Health, Inc. entered into a complex financing arrangement involving the issuance of $4.6 million in Future Advance Convertible Promissory Notes and significant warrants to existing creditors. The transaction involves highly dilutive terms and is structured in connection with an upcoming business combination with SEP Acquisition Corp.
🚩 Red Flags
- Highly dilutive financing: Issuance of over 227 million warrants at extremely low exercise prices ($0.04 and $0.067).
- Death Spiral potential: Conversion price and warrant exercise prices are subject to downward adjustments if the stock price falls or if listed on Nasdaq under certain conditions.
- No new cash infusion: The January 2024 private placement provided no liquidity, merely converting existing debt obligations into new convertible instruments.
- Waiver of reverse split requirement suggests the company was facing delisting pressure/compliance issues regarding minimum bid price.
📋 Key Facts
- Issued $4.6 million in Future Advance Convertible Promissory Notes (the 'Notes') on January 21, 2024.
- The Notes carry a 15% per annum interest rate and can be converted at a price of $0.04 per share.
- Issued warrants to purchase an additional 227.8 million shares (split into two tranches: 113.9M at $0.067/share and 113.9M at $0.04/share).
- The transaction resulted in no new cash proceeds for the company.
- Purchasers received a waiver regarding the requirement to effect a reverse stock split by December 31, 2023.
- The Notes are secured and subordinate to North Haven Expansion Credit Fund Holdings LP.
SANUWAVE Health, Inc. issued a press release announcing preliminary financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is an announcement of preliminary financial results for the period ending December 31, 2023.
- The report was filed on January 10, 2024.
- Preliminary results are provided via a press release attached as Exhibit 99.1.
SANUWAVE Health, Inc. entered into a $1.9 million private placement involving convertible promissory notes and significant warrant coverage. The deal includes complex conversion terms tied to an upcoming business combination with SEP Acquisition Corp (SEPA).
🚩 Red Flags
- Significant dilution risk: The issuance of up to 93 million warrants plus conversion of $1.9M in notes represents massive potential share issuance.
- Death Spiral features: Conversion prices and warrant exercise prices are subject to downward adjustments if the stock price falls or if a Nasdaq listing occurs at low valuations.
- Complex restructuring: The deal is heavily intertwined with an upcoming merger (SEPA), creating high execution risk.
- Waiver of reverse split: Investors waived the requirement for a reverse split, suggesting they are prioritizing immediate liquidity/conversion over maintaining minimum bid price requirements.
📋 Key Facts
- Entered into a Securities Purchase Agreement on December 30, 2023.
- Issued $1.9 million in future advance convertible promissory notes at a 15% annual interest rate.
- Issued two tranches of warrants: 46.5M shares at $0.067 and 46.5M shares at $0.04 per share.
- The conversion price for the Notes is set at $0.04 per share, subject to downward adjustments.
- Purchasers received a waiver of the company's obligation to execute a reverse stock split by December 31, 2023.
- Includes a Letter Agreement where Note/Warrant holders will exchange securities for common stock at specific ratios prior to the SEPA business combination.